top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Rheumatoid Arthritis Drugs Market Shares, Strategies, and Forecasts Analysis

0 votes
5 views

The global rheumatoid arthritis drugs market was valued at US$ 19597.4 Mn in 2016. It is anticipated to expand at a stable CAGR of more than 2.5% between 2018 and 2026, according to a new report published by Transparency Market Research (TMR) titled “Rheumatoid Arthritis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Expansion of the global rheumatoid arthritis drugs market is due to strong research & development and increasing awareness regarding usage of biologic drugs for rheumatoid arthritis treatment during the forecast period. The rheumatoid arthritis drugs market in Asia Pacific is expanding with a high potential to grow, registering a CAGR of more than 3.0% due to the high prevalence of diseases, development in health care sector, and increased focus on research and developmental activities in the region.

Planning To Lay Down Future Strategy? Request Brochure Of Rheumatoid Arthritis Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2011

Rise in geriatric population with increasing incidence of diseases that require drugs to drive market

The global population is aging rapidly, especially in some developed countries such as the U.S., most countries of Western Europe, and Japan. Developed countries witnessed high rates of aging as compared to the developing countries. This is attributed to improved health care infrastructure, reimbursement policies, and advancement in health care facilities in these countries. Moreover, easy access to various drugs treatment has improved in recent years, especially in developed countries. This, in turn, has boosted the life expectancy of the population. The geriatric population is a major end-user of rheumatoid arthritis drugs treatment for the improvement in the quality of their lives. Increase in number of geriatric people leads to high rate of ailments, which in turn is likely to propel the demand and consumption of various drugs.

Rise in investments in research & development

Demand for development of newer and biotechnologically enhanced products such as biologics and biosimilar is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the rheumatoid arthritis drugs market are investing in research and development programs in order to develop new drugs. In 2015, Takeda Pharmaceuticals invested US$ 3.2 Bn in research and development activities. According to an annual report published by GlaxoSmithKline plc, in 2015, the company partnered with more than 1,500 companies and other academic organizations around the world for the development of new drugs. Rise in investment in research and development programs by key players of the market is likely to boost the market significantly during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of Rheumatoid Arthritis Drugs Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2011

Increase in strategic alliances and awareness programs

Major companies focus on strategic alliances for sales and distribution in order to increase business in untapped markets. For instance, Merck, a prominent drug manufacturer, entered into an alliance with Immulogic Pharmaceutical, a startup, in order to develop drugs for auto-immune diseases such as rheumatoid arthritis. Increasing strategic alliances coupled with new product development is expected to boost the rheumatoid arthritis market.

In terms of drug type, the market can be divided into disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (biologics). The biologics segment is likely to account for a leading share of the global rheumatoid arthritis drugs market during the forecast period, owing to the rising adoption of biologic drugs in severe chronic diseases. Strong research and development in biologic drugs is estimated to propel the biologics segment during the forecast period.

Rising patient preference for treatment at hospitals drives hospital pharmacy as a distribution channel

Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is estimated to expand at a prominent growth rate during the forecast period, owing to the increase in number of hospitals.

Increasing prevalence of rheumatoid arthritis in Asia Pacific to create more opportunities for rheumatoid arthritis drugs market

Based on geography, the global rheumatoid arthritis drugs market is divided into major five geographical regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is estimated to hold a leading share of the global market during the forecast period, owing to the high rate of adoption of biologic drugs and high health care expenditure in the region. Europe is anticipated to account for a significant share of the global market between 2018 and 2026. Increase in the incidence of rheumatoid arthritis diseases in Europe is projected to fuel the market in the region during the forecast period. The market in Asia Pacific is projected to witness expansion at a high growth rate during the forecast period, due to increasing health care expenditure in the region. The rheumatoid arthritis drugs market in Latin America is at a pivotal point, currently. It was valued at US$ 866.1 Mn in 2016 and is anticipated to witness significant expansion in the near future.

Increasing focus of key players on expansion in Asia Pacific, in order to cater to the large untapped population, and rising awareness about health care propel the rheumatoid arthritis drugs market in the region.

AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., were market leaders in the rheumatoid arthritis drugs market in 2017

Key players covered in this report include Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company. Companies operating in the global rheumatoid arthritis drugs market are focusing on strategic collaborations in order to develop new products in emerging markets such as Asia Pacific and Latin America.

posted Feb 12 by Rohini Chaudhari

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

The global rheumatoid arthritis drugs market was valued at US$ 19597.4 Mn in 2016. It is anticipated to expand at a stable CAGR of more than 2.5% between 2018 and 2026, according to a new report published by Transparency Market Research (TMR) titled “Rheumatoid Arthritis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Expansion of the global rheumatoid arthritis drugs market is due to strong research & development and increasing awareness regarding usage of biologic drugs for rheumatoid arthritis treatment during the forecast period. The rheumatoid arthritis drugs market in Asia Pacific is expanding with a high potential to grow, registering a CAGR of more than 3.0% due to the high prevalence of diseases, development in health care sector, and increased focus on research and developmental activities in the region.

Planning To Lay Down Future Strategy? Request Brochure Of Rheumatoid Arthritis Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2011

Rise in geriatric population with increasing incidence of diseases that require drugs to drive market

The global population is aging rapidly, especially in some developed countries such as the U.S., most countries of Western Europe, and Japan. Developed countries witnessed high rates of aging as compared to the developing countries. This is attributed to improved health care infrastructure, reimbursement policies, and advancement in health care facilities in these countries. Moreover, easy access to various drugs treatment has improved in recent years, especially in developed countries. This, in turn, has boosted the life expectancy of the population. The geriatric population is a major end-user of rheumatoid arthritis drugs treatment for the improvement in the quality of their lives. Increase in number of geriatric people leads to high rate of ailments, which in turn is likely to propel the demand and consumption of various drugs.

Rise in investments in research & development

Demand for development of newer and biotechnologically enhanced products such as biologics and biosimilar is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the rheumatoid arthritis drugs market are investing in research and development programs in order to develop new drugs. In 2015, Takeda Pharmaceuticals invested US$ 3.2 Bn in research and development activities. According to an annual report published by GlaxoSmithKline plc, in 2015, the company partnered with more than 1,500 companies and other academic organizations around the world for the development of new drugs. Rise in investment in research and development programs by key players of the market is likely to boost the market significantly during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of Rheumatoid Arthritis Drugs Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2011

Increase in strategic alliances and awareness programs

Major companies focus on strategic alliances for sales and distribution in order to increase business in untapped markets. For instance, Merck, a prominent drug manufacturer, entered into an alliance with Immulogic Pharmaceutical, a startup, in order to develop drugs for auto-immune diseases such as rheumatoid arthritis. Increasing strategic alliances coupled with new product development is expected to boost the rheumatoid arthritis market.

In terms of drug type, the market can be divided into disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (biologics). The biologics segment is likely to account for a leading share of the global rheumatoid arthritis drugs market during the forecast period, owing to the rising adoption of biologic drugs in severe chronic diseases. Strong research and development in biologic drugs is estimated to propel the biologics segment during the forecast period.

Rising patient preference for treatment at hospitals drives hospital pharmacy as a distribution channel

Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is estimated to expand at a prominent growth rate during the forecast period, owing to the increase in number of hospitals.

Increasing prevalence of rheumatoid arthritis in Asia Pacific to create more opportunities for rheumatoid arthritis drugs market

Based on geography, the global rheumatoid arthritis drugs market is divided into major five geographical regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is estimated to hold a leading share of the global market during the forecast period, owing to the high rate of adoption of biologic drugs and high health care expenditure in the region. Europe is anticipated to account for a significant share of the global market between 2018 and 2026. Increase in the incidence of rheumatoid arthritis diseases in Europe is projected to fuel the market in the region during the forecast period. The market in Asia Pacific is projected to witness expansion at a high growth rate during the forecast period, due to increasing health care expenditure in the region. The rheumatoid arthritis drugs market in Latin America is at a pivotal point, currently. It was valued at US$ 866.1 Mn in 2016 and is anticipated to witness significant expansion in the near future.

Increasing focus of key players on expansion in Asia Pacific, in order to cater to the large untapped population, and rising awareness about health care propel the rheumatoid arthritis drugs market in the region.

AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., were market leaders in the rheumatoid arthritis drugs market in 2017

Key players covered in this report include Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company. Companies operating in the global rheumatoid arthritis drugs market are focusing on strategic collaborations in order to develop new products in emerging markets such as Asia Pacific and Latin America.

0 votes

The asthma and COPD drugs market in US and China is expected to show a consolidated competitive landscape. In 2015, the leading players within the US and China asthma and COPD drugs Market accounted for 64% of the total Market, according to a recent research report by transparency market research TMR. The names of the leading players within the US and China asthma and COPD drugs market are: Merck & Co. Inc., Astrazeneca plc, Novartis AG, GlaxoSmithKline plc, and Boehringer Ingelheim.

According to the TMR report, the US and China asthma and COPD drugs market will be worth US$18.7 bn by 2024. On the basis of different types or classes of drugs come on the market is segmented into anti-inflammatory drugs, combination drugs, bronchodilators, and monoclonal antibodies. Among these, it is the combination drug segment which is witnessing highest growth. The segment accounted for 54% of the total US market in 2015. The combination drug segment is expected to continue to lead throughout the focus period on account of positive recommendations from organizations such as Global initiative for asthma and Global Initiative for chronic obstructive lung disease, which state that blends the dates are more secure course of treating asthma and COPD.

Request PDF Sample of Asthma and COPD Drugs Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15857

US Accounted for 81% of Market in 2016

On the basis of geography, among the US and China, it is the US which is dominating in the asthma and COPD drugs Market on account of High awareness level among the people regarding the availability of drugs and treatment options. Regular product launches and continues Investments by leading players in the research and development sector will also help the market to grow in the US. In 2016, the US accounted for a whopping 81% of the total market.

Growing Air Pollution Behind Growth in China Asthma and COPD Drugs Market

China on the other hand accounts for the relatively small share in the asthma and COPD drugs Market, but is expected to present liquid growth opportunities for Market players in the coming years. China is expected to exhibit at 10% in the asthma COPD drugs Market. The factors associated with the increasing number of asthma patients, Rising air pollution, and vast unmet medical needs of the patient population. The increasing number of smokers is also an important factor contributed to the growth of the market in China.

Buy Now “Asthma and COPD Drugs Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=15857&ltype=S

Rising Number of Deaths due to COPD and Asthma Behind High Demand for Treatment

According to the lead author of this report, asthma and COPD are two disorders which are affecting a large number of population today and is behind the growth of the US and China asthma and COPD drugs market. These two disorders are increasingly becoming a factor for increased number of deaths and therefore effective treatment is highly in demand. The FDA endorsements for novel treatment options is expected to contribute to the growth of the US and China asthma and COPD drugs market. So the other factors helping the market to grow is the growing geriatric population, lifestyle changes, increasing number of smokers, increase in pollution, and rising industrialization.

0 votes

Global Treatment-Resistant Depression Market – Overview

Depression is a feeling of being sad that interferes with the normal functioning of our regular activities. It also leads to a decreased interest in several general activities. It has several side effects such as emotionally disturbing events, change in internal hormonal levels. Sometimes the effects can be hereditary and at other, the side effects from drugs can lead to depression. Electroconvulsive therapy, psychotherapy, and antidepressants can help patients suffering from depression. Treatment resistant depression is a kind of disorder where the patient does not respond well to the antidepressants used for treating the conditions.

Report overview @ https://www.transparencymarketresearch.com/treatment-resistant-depression-market.html

Global Treatment-Resistant Depression Market – Key Trends

There are various factors that are helping to drive the growth of the global treatment resistant depression market. One of the key augmenting factor for the market development the growing prevalence of depression and anxiety related diseases in adults. Also, this is prevalent in ageing population. The expected prevalence for the stage 1 and stage 2 patients for treatment resistance depression is on the rise. This too is expected to act as a key driving factor for growth of the global market. The growing geriatric population across the globe is also another important factor that is expected to give a solid push to the development of the global treatment resistant depression market.

Global Treatment-Resistant Depression Market – Geographical Outlook

In terms of geographical segmentation, there are five main regions of the global treatment resistant depression market. These regional segments are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Currently, the global market is being dominated by the regional segment of North America. The region is expected to show the highest revenue growth curve over the course of the given period of forecast ranging from 2019 to 2027.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72852

In addition to this, the region has highly developed medical infrastructure and growing spending for development of healthcare facilities has also helped in the growth of the North America region. Furthermore, in recent years, there has been a growing rate of adoption and increasing demand for treatment resistant depression is also expected to drive the regional market. On the other hand, the regional segment of Europe is expected to follow the North America region.

The Asia Pacific region is expected to show a promising rate of growth during the course of the given period of forecast. The region is opening up the previously held taboo of mental health. With growing awareness about mental disorders, depression, and mental health, the regional segment of Asia Pacific is expected to show a promising rate of growth and give rise to lucrative business opportunities for the development of the market in coming years.

Global Treatment-Resistant Depression Market – Competitive Landscape

The vendor landscape of the global treatment resistant depression market is fragmented in nature. This state of the vendor landscape is because of the presence of several notable brands plying their trade in the market space. The companies in the market are focused on developing newer and more effective drugs that will help in catering to the evolving needs of the consumers.

Pre Book Treatment Resistant Depression Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=72852&ltype=S

Moreover, these companies are also expected to resort to adopting inorganic growth strategies such as mergers, acquisitions, takeovers, strategic partnerships and alliances in order to stay ahead of their rivals. Some of the key players in the global market for treatment resistant depression market are Wyeth, Vistagen Therapeutics Inc., Schering Plough Corporation, Janssen Pharmaceuticals Inc., Forest Laboratories, Allergen Plc., Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc., and AstraZeneca Plc. among others.

More Trending Reports by Transparency Market Research –

Porcine Vaccines Market: prnewswire.com/news-releases/porcine-vaccines-market-to-reach-us-3208-mn-by-2025-says-tmr-679503443.html

Medical Imaging Phantoms Market: prnewswire.com/news-releases/medical-imaging-phantoms-market-to-attain-a-value-of-us180-0-million-by-2026—says-tmr-300832758.html

0 votes

Transparency Market Research (TMR) has published a new report titled, ‘Viral Vector & Plasmid DNA Manufacturing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027.’ According to the report, the global viral vector & plasmid DNA manufacturing market was valued at US$ 0.4 Bn in 2018 and is projected to expand at a CAGR of 23.3% from 2019 to 2027.

Overview

  • Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy.
  • There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors. Plasmid DNA is also employed as a vector in gene therapy and vaccinology. Plasmid DNA is used as raw material in the production of various viral vectors.
  • Technological advancements, increase in awareness about viral vector-based treatments, and rise in demand for vector-based products for research are the major factors anticipated to drive the global viral vector & plasmid DNA manufacturing market during the forecast period
  • North America held major share of the global viral vector & plasmid DNA manufacturing market in 2018. Availability of the U.S. FDA (Food and Drug Administration) approved gene therapy products and rich product pipeline are the factors expected to augment the viral vector & plasmid DNA manufacturing market in the region during the forecast period.
  • The viral vector & plasmid DNA manufacturing market in Asia Pacific is likely to expand at a high CAGR of 24.5% from 2019 to 2027, due to recent developments in regenerative medicines, rise in prevalence of chronic diseases, and increase in demand for gene therapies. Additionally, demand for viral vector & plasmid DNA is increasing in emerging markets such as India and China.

Request PDF Sample of Viral Vector & Plasmid DNA Manufacturing Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30428

Rise in Prevalence of Cancer, Genetic Diseases, and Infectious Diseases to Propel Global Viral Vector & Plasmid DNA Manufacturing Market

  • Rise in prevalence of cancer and genetic diseases is projected to augment the global viral vector & plasmid DNA manufacturing market during the forecast period
  • According to the Cancer Research UK, 17 million new cases of cancer were reported globally in 2018 and the four most common types of cancer were breast, lung, bowel, and prostate, which account for around 43% of all new cases
  • According to the National Cancer Institute, cancer is among the leading causes of death across the world, and the number of new cases per year is anticipated to rise to 23.6 million by 2030.

Plasmid DNA Segment Dominated Global Viral Vector & Plasmid DNA Manufacturing Market

  • In terms of type, the global viral vector & plasmid DNA manufacturing market can be classified into lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others
  • The plasmid DNA segment dominated the global viral vector & plasmid DNA manufacturing market in 2018 and the trend is expected to continue during the forecast period
  • Increase in use of plasmid DNA as raw material in the manufacture of viral vectors is likely to drive the segment during the forecast period

Cancer to be Promising Segment of Global Viral Vector & Plasmid DNA Manufacturing Market

  • Based on disease, the global viral vector & plasmid DNA manufacturing market has been categorized into genetic disorders, cancer, infectious diseases, and others
  • The cancer segment dominated the global viral vector & plasmid DNA manufacturing market in 2018 and the trend is projected to continue during the forecast period owing to large number of ongoing clinical trials and availability of approved viral vector-based cancer drugs

Biotech Companies to be Lucrative Segment of Global Viral Vector & Plasmid DNA Manufacturing Market

  • In terms of end-user, the global viral vector & plasmid DNA manufacturing market has been categorized into biotech companies and research institutes
  • The biotech companies segment held major share of the global viral vector & plasmid DNA manufacturing market in 2018
  • Increase in number of viral vector-based cancer drugs being manufactured by multinational players and several clinical trials underway for the treatment of various cancers are anticipated to propel the segment during the forecast period.

Buy Now “Viral Vector & Plasmid DNA Manufacturing Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=30428&ltype=S

North America to Dominate Global Market; Asia Pacific to Offer Significant Incremental Opportunity

  • In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
  • North America is projected to account for major share of the global viral vector & plasmid DNA manufacturing market during the forecast period, owing to high acceptance of viral vector-based gene therapies for the treatment of rare diseases and availability of FDA-approved gene therapies
  • The viral vector & plasmid DNA manufacturing market in Asia Pacific is anticipated to grow at a rapid pace in the next few years. Several ongoing gene therapy clinical trials in countries in China and Japan and high incidence of cancer are likely to fuel the growth of the market in the emerging countries of Asia Pacific

Key Players in Global Viral Vector & Plasmid DNA Manufacturing Market

  • Key players operating in the global viral vector & plasmid DNA manufacturing market include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies, Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza.

More Trending Reports by Transparency Market Research –

Breast Pumps Market: globenewswire.com/news-release/2018/08/23/1555918/0/en/Breast-Pumps-Market-to-Rise-to-US-4-164-6-mn-by-2025-Says-TMR.html

Atrial Fibrillation Market: globenewswire.com/news-release/2019/06/17/1869644/0/en/Atrial-Fibrillation-Market-to-collect-US-10-925-1-million-revenue-by-2026-TMR.html

Eyewear Market: finance.yahoo.com/news/rising-prevalence-chronic-eye-diseases-113000101.html

0 votes

Electromedical Devices Market: Introduction

  • Electromedical devices are medical devices used in various applications in health care industries, including therapeutic use (surgical instruments, laser, and others) and diagnostic use (imaging equipment, monitoring devices)
  • These devices are used in diagnosis and surgical procedures related to cardiovascular, dental, ophthalmology, and other disease indications

Report Overview @ https://www.transparencymarketresearch.com/electromedical-devices-market.html

Key Drivers and Restraints of Global Electromedical Devices Market

  • Increase in research & development activities and technological advancements in electromedical devices are major factors for boosting the growth of the global electromedical devices market during the forecast period. Increase in new product approvals for electromedical devices is another key factor for driving the market. For instance, in 2018, the Food and Drug Administration, approved 106 electromedical devices compared to 99 in 2017.
  • In addition, increase in demand for imaging in diagnosis and monitoring of major chronic diseases related to cardiology and oncology helps drive the market. Heart valve replacement is the most common procedure in cardiology. Increase in use of electromedical devices in heart valve replacement procedure is another main factor for fueling the growth of this market. Moreover, new product launches from major manufacturers are anticipated to propel the electromedical devices market. In August 2018, Invacare Corporation launched an advanced carbon fibre racing wheelchair for rehabilitation patients.
  • High cost and high technical configuration required for electromedical devices restrain the electromedical devices market

Get a Glimpse of the In-Depth Analysis through our Comprehensive “Electromedical Devices Market” Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75413

Diagnostic Imaging Devices Segment to Witness High Demand

  • Based on device type, the global electromedical devices market can be segmented into diagnostic imaging devices, surgical devices, patient assistive devices, and others
  • The diagnostic imaging devices segment accounted for the highest share of the electromedical devices market in 2018. This segment is expected to dominate the electromedical devices market due to increase in incidence of major chronic diseases which further resulted into rise in demand for disease diagnosis. In addition, launch of new diagnostic imaging devices in recent years is expected to drive the segment.

Cardiovascular Application Segment to Witness Significant Growth

  • In terms of application, the global electromedical devices market can be divided cardiovascular, dental, ophthalmology, orthopedic, and others
  • The cardiovascular segment generated the highest revenue in 2018 and is anticipated to witness growth during the forecast period. This can be attributed to rise in incidence of cardiovascular disorders.

Hospitals Segment to be Most Promising Segment

  • In terms of end-user, the global electromedical devices market can be divided into hospitals, clinics, home care settings, and others. The hospitals segment generated the highest revenue in 2018 and is anticipated to witness growth during the forecast period.
  • Most of the electromedical devices are available in hospitals and increase in demand for electromedical devices in newly set up hospitals helps drive the segment

North America to Dominate Global Electromedical Devices Market

  • In terms of region, the global electromedical devices market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global electromedical devices market in 2018 and is expected to maintain its leading position during the forecast period. Dominance of the region can be attributed to increase in product offerings, new product launch, presence of key market players in the region, and greater affordability. For instance, in October 2018, the B. Braun Melsungen AG received USFDA approval for ELAN 4 Electro Motor system, which used in the spinal and neurological surgical procedures.
  • The market in Asia Pacific is projected to register highest growth during the forecast period, owing to increase in adoption of new products, and rise in incidence of cardiovascular, orthopedic, and ophthalmology disorders

Pre Book “Electromedical Devices Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=75413&ltype=S

Key Manufacturers Operating in Global Market

The global electromedical devices market was highly fragmented in 2018. Key manufacturers operating in the global market are:

  • Medtronic plc
  • GENERAL ELECTRIC Healthcare
  • B. Braun Melsungen AG
  • Siemens AG
  • Koninklijke Philips N.V.
  • Cardinal Health
  • Zimmer Biomet
  • Abbott
  • Stryker Corporation
  • 3M
...